MetaCap

Nomad Power Solutions (NMAD) vs RenovoRx (RNXT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

RenovoRx (RNXT) has outperformed Nomad Power Solutions (NMAD) over the past year, gaining 18.3% versus a loss of 40.6%. Over five years, NMAD leads with a -84.6% price change compared with -85.3% for RNXT. Nomad Power Solutions is the larger company by market cap ($47.2 million vs $45.5 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NMAD-40.60%RNXT+18.34%
+230%+84%-61%
Nov 21, 20251 yearNov 20, 2026
NMAD-85.12%RNXT-85.71%
+30%-36%-102%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NMAD versus RNXT key metrics
MetricNMADRNXT
Share price$2.56$0.942
Market cap$47.15M$45.45M
1-day change+13.53%-10.29%
YTD return-34.86%+12.14%
1-year return-40.60%+18.34%
5-year return-84.58%-85.26%
EPS (TTM)$-1.01$-0.31
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$1.12M
Revenue growth (YoY)—+2511.63%
Net income (latest FY)$-6.08M$-11.17M
Gross margin—70.88%
Operating margin—-1113.98%
Net margin—-994.48%
52-week high$8.38$2.59
52-week low$2.13$0.77
Distance from 52-week high-69.45%-63.63%
Analyst consensus—none
Avg. price target upside—+656.90%
Average volume228.96K815.75K
Shares outstanding18.42M48.25M
Employees—17
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • RNXT has outperformed NMAD by 58.9 percentage points over the past year.

About Nomad Power Solutions

NMAD stock →

NOMAD Power Solutions, Inc. develops utility-scale mobile energy storage systems on providing transportable solutions.

Health Care · Biotechnology: Pharmaceutical Preparations

About RenovoRx

RNXT stock →

RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees

NMAD vs RNXT FAQ

Which is bigger, Nomad Power Solutions or RenovoRx?

Nomad Power Solutions (NMAD) is larger, with a market capitalization of $47.15M compared with $45.45M for RenovoRx (RNXT).

Which stock has performed better over the past year, NMAD or RNXT?

RNXT returned +18.34% over the past 12 months, compared with -40.60% for NMAD (price return, excluding dividends). Past performance does not predict future results.

Are Nomad Power Solutions and RenovoRx in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons